Translating the Why WAIT Toolkit for Primary Care Practie

为初级保健实践翻译 Why WAIT 工具包

基本信息

  • 批准号:
    8323268
  • 负责人:
  • 金额:
    $ 21.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-23 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Translating the Why WAIT Toolkit for Primary Care Practice will adapt the behavioral intervention component of the Why WAIT program and evaluate the feasibility of implementing it in primary care practices. The primary goal is to translate one component of the current and highly successful Why WAIT program into a model that can be widely disseminated to the primary care setting, where more than 85% of patients with diabetes receive their health care in the US and to evaluate the feasibility of implementing the adapted program in that setting. The specific aims are: Aim 1 Program Adaptation: Translate the behavioral therapy component of the successful Why WAIT program to primary care practices (PCP) with appropriate delivery approaches and messaging for both patients and providers. Aim 2 Feasibility assessment: Evaluate the feasibility of implementing the adapted component in primary care setting through program evaluation and qualitative research with providers and patients. Aim 3 Design of randomized trial for full scale evaluation: Finalize study design of the randomized controlled trial and recruit sufficient primary care practice sites for a randomized controlled trial of the fully adapted Why WAIT program Upon successful completion of the proposed objectives, we will be in a position adapt the entire program and to fully test it using a rigorous cluster randomized trial that maximizes generalizabity and minimizes bias. The innovative combination of interpersonal contact with media based support will result in a Why WAIT program that will be a extremely useful for PCPs, operating within known constraints, such as time and resources. The qualitative in-depth discussion with PCPs and diabetes patients, will inform the translation of the Why WAIT program to address the needs and obstacles faced by this audience. This will result in a program that will be used effectively by PCPs to reach a larger proportion of the diabetes population and will have a greater Public Health impact through weight reduction and diabetes management than programs located in specialty clinics. The final result of this effort will increase the opportunities to provide the tools to patients to manage their disease and thereby to reduce the mortality and morbidity consequences of T2DM.
描述(由申请人提供):翻译为什么等待初级保健实践工具包将适应为什么等待程序的行为干预组成部分,并评估在初级保健实践中实施的可行性。主要目标是将当前非常成功的Why WAIT计划的一个组成部分转化为可以广泛传播到初级保健环境的模型,其中超过85%的糖尿病患者在美国接受医疗保健,并评估在该环境中实施适应计划的可行性。具体目标是:目标1方案调整:将成功的Why Wait计划的行为治疗部分转化为初级保健实践(PCP),并为患者和提供者提供适当的交付方法和信息。目标2可行性评估:通过项目评估和与提供者和患者的定性研究,评估在初级保健环境中实施适应性组件的可行性。目的3全规模评价的随机试验设计:确定随机对照试验的研究设计,并招募足够的基层医疗机构进行完全适应的Why WAIT计划的随机对照试验。在成功完成拟议的目标后,我们将能够适应整个计划,并使用严格的随机分组试验进行全面测试,最大限度地提高普遍性,最大限度地减少偏倚。人际接触与基于媒体的支持的创新组合将导致一个为什么等待计划,这将是一个非常有用的PCP,在已知的限制,如时间和资源。与PCP和糖尿病患者的定性深入讨论将为Why Wait计划的翻译提供信息,以解决这一受众面临的需求和障碍。这将产生一个计划,该计划将被PCP有效地用于更大比例的糖尿病人群,并将通过减肥和糖尿病管理产生比专业诊所更大的公共卫生影响。这一努力的最终结果将增加为患者提供管理其疾病的工具的机会,从而降低T2DM的死亡率和发病率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anne M. Stoddard其他文献

1676: Results of the Sister Randomized Surgical Trial Comparing the Autologous Rectus Fascia Sling to the Burch Colposuspension
  • DOI:
    10.1016/s0022-5347(18)31864-0
  • 发表时间:
    2007-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Michael E. Albo;Holly E. Richter;Linda Brubaker;Peggy A. Norton;Stephen Kraus;Philippe E. Zimmern;Toby C. Chai;Halina Zcysynski;Ananias C. Diokno;Charles Nager;L. Keith Lloyd;Mary P. FitzGerald;Gary E. Lemack;Harry Johnson;Wendy Lang;Veronica T. Mallett;Sharon Tennstedt;Anne M. Stoddard;John W. Kusek;Leroy M. Nyberg
  • 通讯作者:
    Leroy M. Nyberg
Cancer prevention practices and continuing education needs of primary care physicians.
初级保健医生的癌症预防实践和继续教育需求。
1181: Voiding Symptoms are Common in Women Planning Continence Surgery
  • DOI:
    10.1016/s0022-5347(18)31395-8
  • 发表时间:
    2007-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Peggy A. Norton;Holly E. Richter;Toby C. Chai;Michael E. Albo;Mary P. FitzGerald;Anne M. Stoddard;Philippe E. Zimmem
  • 通讯作者:
    Philippe E. Zimmem
Local labor unions' positions on worksite tobacco control.
当地工会对工作场所控烟的立场。
  • DOI:
    10.2105/ajph.90.4.618
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    12.7
  • 作者:
    G. Sorensen;Anne M. Stoddard;R. Youngstrom;Karen M. Emmons;E. Barbeau;F. Khorasanizadeh;Charles Levenstein
  • 通讯作者:
    Charles Levenstein
McCusker and Stoddard Respond
麦卡斯克和斯托达德回应
  • DOI:
    10.2105/ajph.83.9.1350
  • 发表时间:
    1993
  • 期刊:
  • 影响因子:
    12.7
  • 作者:
    J. Mccusker;Anne M. Stoddard
  • 通讯作者:
    Anne M. Stoddard

Anne M. Stoddard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anne M. Stoddard', 18)}}的其他基金

Translating the Why WAIT Toolkit for Primary Care Practie
为初级保健实践翻译 Why WAIT 工具包
  • 批准号:
    8183102
  • 财政年份:
    2011
  • 资助金额:
    $ 21.34万
  • 项目类别:
Pediatric Heart network DCC
儿科心脏网络 DCC
  • 批准号:
    8491912
  • 财政年份:
    2001
  • 资助金额:
    $ 21.34万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.34万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了